Strategies to improve the killing of tumors using temozolomide: Targeting the DNA repair protein MGMT

Current Medicinal Chemistry

Volumn 19, Issue 23, 2012, Pages 3886-3892

  Jiang, G ^a,b   Li, L T ^a   Xin, Y ^a   Zhang, L ^b   Liu, Y Q ^a   Zheng, J N ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Xuzhou City   (China)

Author keywords

cancer therapy; DNA repair; MGMT; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; BETA INTERFERON; CHECKPOINT KINASE 2; ETIRACETAM; GENOMIC DNA; INTERLEUKIN 24; LOMEGUATRIB; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONCOLYTIC VIRUS; PROTEIN KINASE C; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SP1;

ACUTE LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING COMPETITION; BIOAVAILABILITY; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; COMPETITIVE INHIBITION; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INACTIVATION; EXCISION REPAIR; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTHERMIC THERAPY; LIPOSOMAL DELIVERY; MELANOMA; NASOPHARYNX CARCINOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PANCREAS CANCER; PROMOTER REGION; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; DACARBAZINE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; ONCOLYTIC VIRUSES; RNA INTERFERENCE;

EID: 84865710479     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802002446     Document Type: Review

References (94)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2011; 60(5):277-300.
2. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13(16):1859-1876.
3. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primarybrain tumours. Eur J Cancer. 1993;29A(7):940-942. (Pubitemid 23126688)
4. Yoshimoto Y, Augustine CK, Yoo JS, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther. 2007;6(5):1492-1500. (Pubitemid 46954016)
5. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17(9):2762-2771. (Pubitemid 29415233)
6. Rietschel P, Wolchok JD, Krown S, et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol. 2008;26(14):2299-2304.
7. []Middlemas DS, Stewart CF, Kirstein MN, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res. 2000;6(3):998-1007. (Pubitemid 30159360)
8. Plummer ER, Middleton MR, Jones C, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADPribose) polymerase-1. Clin Cancer Res. 2005;11(9):3402-3409. (Pubitemid 40627893)
9. Tentori L, Orlando L, Lacal PM, et al. Inhibition of O6-alkylguanine DNAalkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol. 1997;52(2):249-258. (Pubitemid 27349616)
10. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 1993;362(6421):652-654. (Pubitemid 23109278)
11. Hooper NI, Tisdale MJ, Thornalley PJ. Glyoxalase activity during differentiation of human leukaemia cells in vitro. Leuk Res. 1987;11(12):1141-1148. (Pubitemid 18049496)
12. Dive C, Workman P, Watson JV. Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry. Cancer Chemother Pharmacol. 1989;25(3):149-155. (Pubitemid 20009817)
13. Passagne I, Evrard A, Depeille P, Cuq P, Cupissol D, Vian L. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol. 2006;211(2):97-105. (Pubitemid 43238303)
14. Costello JF, Futscher BW, Kroes RA, Pieper RO. Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol Cell Biol. 1994;14(10):6515-6521.
15. Ohno T, Hiraga J, Ohashi H, et al. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol. 2006;83(4):341-347. (Pubitemid 43807580)
16. Brell M, Tortosa A, Verger E, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11(14):5167-5174. (Pubitemid 41003702)
17. Boeckmann L, Thoms KM, Gutzmer R, et al. Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro. Int J Clin Pharmacol Ther. 2009;47(1):33-35.
18. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
19. van Nifterik KA, van den Berg J, van der Meide WF, et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer. 2010;103(1):29-35.
20. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26(2):186-197. (Pubitemid 46095730)
21. Tentori L, Leonetti C, Scarsella M, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002;99(6):2241-2244. (Pubitemid 34525513)
22. Tentori L, Turriziani M, Franco D, et al. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia. 1999;13(6):901-909. (Pubitemid 29292141)
23. Caporali S, Falcinelli S, Starace G, et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol. 2004;66(3):478-491. (Pubitemid 39329246)
24. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 1994;33(31):9045-9051. (Pubitemid 24272851)
25. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307. (Pubitemid 38525285)
26. Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11(3):281-291.
27. Augustine CK, Yoo JS, Potti A, et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res. 2009;15(2):502-510.
28. Alvino E, Castiglia D, Caporali S, et al. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol. 2006;29(4):785-797.
29. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 2009;29(10):3759-3768.
30. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15(1):338-345.
31. Karran P, Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res. 1992;20(12):2933-2940.
32. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst). 2004;3(8-9):1091-1101. (Pubitemid 38997952)
33. Yoshioka K, Yoshioka Y, Hsieh P. ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell. 2006;22(4):501-510.
34. Jiricny J. MutLalpha: at the cutting edge of mismatch repair. Cell. 2006;126(2):239-241. (Pubitemid 44092971)
35. O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis. 2006;27(4):682-692.
36. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-4199.
37. Rabik CA, Njoku MC, Dolan ME. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev. 2006;32(4):261-276. (Pubitemid 44522815)
38. Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol. 1997;40(3):266-272. (Pubitemid 27258665)
39. Ueno T, Ko SH, Grubbs E, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther. 2006;5(3):732-738.
40. Koch D, Hundsberger T, Boor S, Kaina B. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol. 2007;82(1):85-89.
41. Quinn JA, Jiang SX, Reardon DA, et al. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009;11(5):556-561.
42. Verbeek B, Southgate TD, Gilham DE, Margison GP. O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull. 2008;85:17-33.
43. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23(28):7178-7187.
44. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27(8):1262-1267.
45. Broniscer A, Gururangan S, MacDonald TJ, et al. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res. 2007;13(22 Pt 1):6712-6718. (Pubitemid 350206808)
46. Middleton MR, Kelly J, Thatcher N, et al. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer. 2000;85(2):248-252. (Pubitemid 30023075)
47. Barvaux VA, Lorigan P, Ranson M, et al. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther. 2004;3(10):1215-1220. (Pubitemid 39440166)
48. Clemons M, Kelly J, Watson AJ, et al. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer. 2005;93(10):1152-1156. (Pubitemid 41670700)
49. Turriziani M, Caporaso P, Bonmassar L, et al. O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res. 2006;53(4):317-323. (Pubitemid 43670505)
50. Ranson M, Middleton MR, Bridgewater J, et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2006;12(5):1577-1584.
51. Middleton MR, Thatcher N, McMurry TB, McElhinney RS, Donnelly DJ, Margison GP. Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer. 2002;100(5):615-617. (Pubitemid 34816164)
52. Watson AJ, Middleton MR, McGown G, et al. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer. 2009;100(8):1250-1256.
53. Watson AJ, Sabharwal A, Thorncroft M, et al. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res.2010;16(2):743-749.
54. Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-148. (Pubitemid 44921992)
55. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999;34(2-3):161-168. (Pubitemid 29155487)
56. Bobustuc GC, Baker CH, Limaye A, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. 2010;12(9):917-927.
57. Murphy M, Ahn J, Walker KK, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999;13(19):2490-2501. (Pubitemid 29489641)
58. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res. 2002;8(9):2985-2991. (Pubitemid 35025748)
59. Liu L, Yan L, Donze JR, Gerson SL. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol Cancer Ther. 2003;2(10):1061-1066.
60. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomidemediated cell death. Cancer Res. 2005;65(14):6394-6400. (Pubitemid 40994427)
61. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12(2):328-331. (Pubitemid 43166117)
62. Jiang G, Xin Y, Zheng JN, Liu YQ. Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: A novel antitumor approach. 2011;Int J Cancer. Jan 20.
63. Jiang G, Wei ZP, Pei DS, Xin Y, Liu YQ, Zheng JN. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. Biochem Biophys Res Commun. 2011;406(3):311-314.
64. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594-604. (Pubitemid 37328926)
65. Marchetti A, Cecchinelli B, D'Angelo M, et al. p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Differ. 2004;11(6):596-607. (Pubitemid 38786708)
66. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8(5):345-357. (Pubitemid 29131356)
67. Grombacher T, Eichhorn U, Kaina B. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene. 1998;17(7):845-851. (Pubitemid 28430207)
68. Srivenugopal KS, Shou J, Mullapudi SR, Lang FF, Jr., Rao JS, Ali-Osman F. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res. 2001;7(5):1398-1409. (Pubitemid 32708697)
69. Harris LC, Remack JS, Houghton PJ, Brent TP. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res. 1996;56(9):2029-2032. (Pubitemid 26119903)
70. Bocangel D, Sengupta S, Mitra S, Bhakat KK. p53-Mediated downregulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009;29(10):3741- 3750.
71. Vannucchi S, Chiantore MV, Mangino G, et al. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr Med Chem. 2007;14(6):667-679. (Pubitemid 46477719)
72. Yoshino A, Katayama Y, Yokoyama T, et al. Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J Neurooncol. 2005;74(3):249-260. (Pubitemid 41444490)
73. Natsume A, Ishii D, Wakabayashi T, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005;65(17):7573-7579. (Pubitemid 41297227)
74. Rosati SF, Williams RF, Nunnally LC, et al. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol Cancer Ther. 2008;7(12):3852-3858.
75. Yoshino A, Ogino A, Yachi K, et al. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int J Oncol. 2009;35(1):139-148.
76. Natsume A, Wakabayashi T, Ishii D, et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol. 2008;61(4):653-659.
77. Huang EY, Madireddi MT, Gopalkrishnan RV, et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene. 2001;20(48):7051-7063. (Pubitemid 33052197)
78. Emdad L, Lebedeva IV, Su ZZ, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther. 2009;8(5):391-400.
79. Gupta P, Su ZZ, Lebedeva IV, et al. mda-7/IL-24: multifunctional cancerspecific apoptosis-inducing cytokine. Pharmacol Ther. 2006;111(3):596-628. (Pubitemid 44118431)
80. Zheng M, Bocangel D, Ramesh R, et al. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008;7(12):3842-3851.
81. Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther. 2002;12(5):530-537.
82. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002;9(12):967-978. (Pubitemid 35462560)
83. Weitzman MD, Carson CT, Schwartz RA, Lilley CE. Interactions of viruses with the cellular DNA repair machinery. DNA Repair (Amst). 2004;3(8-9):1165- 1173. (Pubitemid 38997960)
84. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther. 2006;6(11):1585-1592. (Pubitemid 44883961)
85. Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007;67(24):11499-11504.
86. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst. 2006;98(1):38-50. (Pubitemid 43057091)
87. Hannon GJ. RNA interference. Nature. 2002;418(6894):244-251. (Pubitemid 34773784)
88. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther. 2006;13(6):464-477.
89. Kuo CC, Liu JF, Chang JY. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J Pharmacol Exp Ther. 2006;316(2):946-954.
90. Kato T, Natsume A, Toda H, et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 2010;17(11):1363-1371.
91. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487-497. (Pubitemid 34863670)
92. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33-56. (Pubitemid 34722786)
93. Pagani E, Falcinelli S, Pepponi R, et al. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity. Int J Oncol. 2007;30(2):443-451.
94. Fukushima T, Takeshima H, Kataoka H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 2009;29(11):4845-4854.